Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
levodopa/carbidopa ER (WD-1603) / China NT Pharma
NCT05036473: A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease	Recruiting	2	40	RoW	WD-1603 Carbidopa-Levodopa Extended-Release Tablets, WD-1603, Placebo, Placebo of WD-1603	Shanghai WD Pharmaceutical Co., Ltd.	Parkinson Disease	05/22	09/22
NCT04513340: WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects	Recruiting	1	8	RoW	WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	Parkinson Disease	09/20	02/21
NCT04553978: A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions	Not yet recruiting	1	8	NA	WD-1603	Hong Kong WD Pharmaceutical Co., Limited	Parkinson Disease	03/21	03/21
NCT04591535: PK Study of WD-1603 in Healthy Subjects	Recruiting	1	8	RoW	WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS, WD-1603	Hong Kong WD Pharmaceutical Co., Limited	Parkinson Disease	03/21	03/21
NCT05128175: Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions	Recruiting	1	15	RoW	WD-1603 Carbidopa-Levodopa Extended-Release Tablets, WD-1603	Shanghai WD Pharmaceutical Co., Ltd.	Parkinson Disease	01/22	03/22